Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1983 1
1990 3
2004 1
2006 1
2008 1
2009 1
2010 2
2012 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023/24 season.
Núñez O, Olmedo C, Moreno-Perez D, Lorusso N, Fernández Martínez S, Pastor Villalba PE, Gutierrez Á, Alonso Garcia M, Latasa P, Sancho R, Mendioroz J, Martinez-Marcos M, Muñoz Platón E, García Rivera MV, Pérez-Martinez O, Álvarez-Gil R, Rivas Wagner E, López Gonzalez-Coviella N, Zornoza M, Barranco MI, Pacheco MDC, Álvarez Río V, Fiol Jaume M, Morey Arance R, Adiego Sancho B, Mendez Diaz M, Batalla N, Andreu C, Castilla J, García Cenoz M, Fernández Ibáñez A, Huerta Huerta M, Ibáñez Pérez AC, Berradre Sáenz B, Lamas J, Hermoso L, Casado Cobo S, Galán Cuesta M, Montenegro S, Domínguez M, Jarrín I, Limia A, Pastor-Barriuso R, Monge S; Nirsevimab Effectiveness Study Collaborators. Núñez O, et al. Among authors: batalla n. Euro Surveill. 2025 Feb;30(5):2400596. doi: 10.2807/1560-7917.ES.2025.30.5.2400596. Euro Surveill. 2025. PMID: 39916606 Free PMC article.
[Cardiac lipoma presenting as angina].
Rafel J, Pujadas R, Batalla N. Rafel J, et al. Among authors: batalla n. Rev Esp Cardiol. 2004 Sep;57(9):884. Rev Esp Cardiol. 2004. PMID: 15373994 Free article. Spanish. No abstract available.
Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year.
Ferreira-González I, Marsal JR, Ribera A, Permanyer-Miralda G, García-Del Blanco B, Martí G, Cascant P, Masotti-Centol M, Carrillo X, Mauri J, Batalla N, Larrousse E, Martín E, Serra A, Rumoroso JR, Ruiz-Salmerón R, de la Torre JM, Cequier A, Gómez-Hospital JA, Alfonso F, Martín-Yuste V, Sabatè M, García-Dorado D. Ferreira-González I, et al. Among authors: batalla n. J Am Coll Cardiol. 2012 Oct 9;60(15):1333-9. doi: 10.1016/j.jacc.2012.04.057. Epub 2012 Sep 19. J Am Coll Cardiol. 2012. PMID: 22999716 Free article.
Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.
Bertrand OF, Poirier P, Rodés-Cabau J, Rinfret S, Title LM, Dzavik V, Natarajan M, Angel J, Batalla N, Alméras N, Costerousse O, De Larochellière R, Roy L, Després JP; VICTORY Trial Investigators. Bertrand OF, et al. Among authors: batalla n. Atherosclerosis. 2010 Aug;211(2):565-73. doi: 10.1016/j.atherosclerosis.2010.06.005. Epub 2010 Jun 11. Atherosclerosis. 2010. PMID: 20594555 Clinical Trial.
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.
Bertrand OF, Poirier P, Rodés-Cabau J, Rinfret S, Title L, Dzavik V, Natarajan M, Angel J, Batalla N, Alméras N, Costerousse O, De Larochellière R, Roy L, Després JP; VICTORY trial investigators. Bertrand OF, et al. Among authors: batalla n. Can J Cardiol. 2009 Sep;25(9):509-15. doi: 10.1016/s0828-282x(09)70136-9. Can J Cardiol. 2009. PMID: 19746240 Free PMC article. Clinical Trial.
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.
Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW; APPROACH Study Group. Gerstein HC, et al. Circulation. 2010 Mar 16;121(10):1176-87. doi: 10.1161/CIRCULATIONAHA.109.881003. Epub 2010 Mar 1. Circulation. 2010. PMID: 20194881 Clinical Trial.
Usefulness of fractional flow reserve measurements to defer revascularization in patients with stable or unstable angina pectoris, non-ST-elevation and ST-elevation acute myocardial infarction, or atypical chest pain.
Potvin JM, Rodés-Cabau J, Bertrand OF, Gleeton O, Nguyen CN, Barbeau G, Proulx G, De Larochellière R, Déry JP, Batalla N, Dana A, Facta A, Roy L. Potvin JM, et al. Among authors: batalla n. Am J Cardiol. 2006 Aug 1;98(3):289-97. doi: 10.1016/j.amjcard.2006.02.032. Epub 2006 Jun 6. Am J Cardiol. 2006. PMID: 16860011
15 results